5 mg BI 1569912

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Depressive Disorder, Major

Phase 1

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

CompletedNCT04937829

Boehringer IngelheimDepressive Disorder, Major

Start: 2021-07-20End: 2023-11-16Updated: 2026-08-14

Phase 2

A Study to Test Different Doses of BI 1569912 in People With Depression

CompletedNCT06558344

Boehringer IngelheimDepressive Disorder, Major

Start: 2024-10-01End: 2025-05-12Updated: 2026-05-22